Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Vera Therapeutics ( (VERA) ) has shared an announcement.
On December 9, 2025, Vera Therapeutics, Inc. announced a follow-on public offering of 6,138,108 shares of its Class A common stock at a price of $42.50 per share, expected to generate approximately $260.9 million in gross proceeds. The offering, set to close on December 11, 2025, includes an option for underwriters to purchase an additional 920,716 shares, which was fully exercised on December 10, 2025. This move is part of Vera Therapeutics’ strategy to strengthen its financial position and potentially expand its market presence, with implications for stakeholders depending on market conditions and other external factors.
The most recent analyst rating on (VERA) stock is a Buy with a $97.00 price target. To see the full list of analyst forecasts on Vera Therapeutics stock, see the VERA Stock Forecast page.
Spark’s Take on VERA Stock
According to Spark, TipRanks’ AI Analyst, VERA is a Underperform.
Vera Therapeutics’ overall stock score is driven by ongoing financial challenges, including consistent losses and negative cash flows, despite a strong equity position. Technical analysis indicates bearish momentum, with the stock underperforming key moving averages. The valuation is unattractive due to a negative P/E ratio and no dividend yield.
To see Spark’s full report on VERA stock, click here.
More about Vera Therapeutics
Average Trading Volume: 1,562,538
Technical Sentiment Signal: Strong Buy
Current Market Cap: $2.88B
Find detailed analytics on VERA stock on TipRanks’ Stock Analysis page.